Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | AXL positive |
| Therapy | ADCT-601 |
| Indication/Tumor Type | renal cell carcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| AXL positive | renal cell carcinoma | sensitive | ADCT-601 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, treatment with ADCT-601 induced DNA interstrand crosslinking and inhibited growth of an AXL-positive renal cell carcinoma cell line in culture and at the highest tested dose resulted in a partial response in 1/8, complete responses in 7/8, and tumor-free survival in 6/8 cell line xenograft models (PMID: 35086955). | 35086955 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (35086955) | Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers. | Full reference... |